Use of phisiotens for treatment of essential hypertension in aged patients

Terapevticheskii Arkhiv

Volumn 73, Issue 9, 2001, Pages 17-22

  Ostroumova, O D ^a   Mamaev, V I ^a   Bagramova, Yu A ^a   Rybkina, T E ^a   Kuzmichev, I A ^a  

^a NONE

Author keywords

Antihypertensive therapy; Arterial hypertension; Monoxidin (phisiotens); The elderly

Indexed keywords

ANTIHYPERTENSIVE AGENT; IMIDAZOLE DERIVATIVE; MOXONIDINE;

AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MALE; MEMORY; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; THINKING;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MEMORY; MIDDLE AGED; QUALITY OF LIFE; THINKING;

EID: 0035237178     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Abrams W. B., Beers M. H., Berkow R. (eds) The Merck manual of geriatrics. New York; 1995. 494-513.
2. Reid J. L., Wing L. M., Dargie H. J. et al. Clonidine withdrawal in hypertension: changes in blood-pressure and plasma and urinary noradrenaline. Lancet 1977; 1: 1171-1174.
3. Schwarz W., Kandziora J. Langzeiterfahrungen mit Moxonidin, einem neuen antihypertensivum. Fortschr. Med. 1990; 32: 616-620.
4. Theodor R., Weimann H.-J., Weber W. et al. Absolute bioavailability of moxonidine. Eur. J. Drug Metab. Pharmacokinet. 1991; 16(2): 153-159.
5. Trenk D., Wagner F., Jahnchen E. et al. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J. Clin. Pharmacol. 1987; 27: 988-993.
6. Kuppers H. E., Jager B. A., Luszick J. H. et al. Placebo controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. J. Hypertens. 1997; 15: 93-97.
7. Hamilton C. A. Chemistry, mode of action and experimental pharmacology of moxonidine. In: van Zwieten P. A. et al., eds. The putative 1 1-imidazoline receptor agonist moxonidine. 2nd ed. London; 1996; 7: 30.
8. Kirch W., Hutt H.-J., Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin. Pkharmacokinet. 1988; 15: 245-253.
9. Mitrovic V., Patyna W. Huting J., Schlepper M. Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc. Drugs Ther. 1991; 5: 967-972.
10. Guidelines Subcommittee. 1999. World Health Organization. International Society of Hypertension. Guidelines for the Management of Hypertension. J. Hypertens. 1999; 17 (2): 151-183.
11. Tep. apx. 1994; 8: 70-73.
12. Devereux R., Reichek N. Echocardiographic assessment of left ventricular mass in man. Circulation 1977; 55: 613-618.
13. Hanson L. Left ventricular hypertrophy. High Blood Pressure 1993; 2 (suppl. 1): 2-4.
14. Kannel W. B. In: Cruickshenck J. M., ed. Left ventricular hypertrophy and regression. London; 1992; 359: 1600-1603.
15. Levy D., Savage D., Garrison K. et al. Echocardiographic criterior for the left ventricular hypertrophy: the Fremingham heart study. Am. J. Cardiol. 1987; 59: 956-960.
16. Cooper R. S., Simmons B., Castaner A. et al. Left ventricular hypertrophy is associated with survival independent of left ventricular function and coronary arteries severy narrowed. A. J. Cardiol. 1990; 65: 441-445.
17. Leonetti G., Comerio G., Cuspidi C. et al. Evaluating quality of life in hypertensive patients. Cardiovasc. Pharmacol. 1994; 23 (suppl. 5): 45-47.
18. Benetos A., Albaladejo P., Levy B. J. Acute and long-term of angiotensin-converting enzyme on arteries and cardia hypertrophy: mechanical and structural parameters. J. Hypertens. 1994; 12 (suppl. 4): 21.